Oral Sessions
（Day1, Day2, Day3, Day4）
Poster Presentations
（Day1, Day2, Day3, Day4）
Luncheon Seminars
（Day1, Day2, Day3, Day4）
Oral Sessions
- Day 3, May 17（Thu.） 09:40-10:00 Room C (Seiun 2)
-
3C-O1-M-0940 PDF
Discovery of biomarkers for glioblastoma multiforme from cerebrospinal fluid by quantitative proteomics
Glioblastoma (GBM) is usually diagnosed by magnetic resonance imaging (MRI). Standard first-line treatment for GBM is a surgery followed by radiation and chemotherapy. However, the diagnosis followed by first-line treatment of GBM remains a challenging issue because the MRI pattern of tumor recurrence is frequently indistinguishable from that of pseudoprogression. Therefore, other diagnostic biomarkers of recurrent malignant brain tumors are required. The purpose of the current study was to use quantitative proteomics to identify diagnostic markers for detecting recurrent glioblastoma (GBM) by comparing the cerebrospinal fluid (CSF) collected from individual patients with GBM at preoperative, postoperative, and recurrence stages with that of individuals without brain tumors. We identified 18 tryptic digest peptides as marker candidates that could discriminate between preoperative and postoperative cases, and between postoperative and recurrent cases. Furthermore, 6 peptides were extracted by excluding multicollinearity. Multivariate analysis with these 6 candidate peptides could distinguish the recurrence from postoperative group with AUC = 0.86 using ROC analysis. These results suggest that 6 peptides are identified in the CSF as marker candidates for discriminating between patients with preoperative, postoperative, and recurrent brain tumors.